Congress Asset Management Co. MA Sells 910 Shares of Johnson & Johnson (JNJ)
Congress Asset Management Co. MA trimmed its position in Johnson & Johnson (NYSE:JNJ) by 1.1% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 82,842 shares of the company’s stock after selling 910 shares during the period. Congress Asset Management Co. MA’s holdings in Johnson & Johnson were worth $10,318,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in JNJ. Willis Investment Counsel lifted its holdings in Johnson & Johnson by 6.7% in the 4th quarter. Willis Investment Counsel now owns 251,183 shares of the company’s stock valued at $28,939,000 after purchasing an additional 15,775 shares in the last quarter. Thomas J. Herzfeld Advisors Inc. purchased a new position in Johnson & Johnson in the 4th quarter valued at about $117,000. Sandler Capital Management lifted its holdings in Johnson & Johnson by 6.1% in the 4th quarter. Sandler Capital Management now owns 2,335 shares of the company’s stock valued at $269,000 after purchasing an additional 135 shares in the last quarter. Miles Capital Inc. lifted its holdings in Johnson & Johnson by 8.7% in the 4th quarter. Miles Capital Inc. now owns 12,997 shares of the company’s stock valued at $1,497,000 after purchasing an additional 1,044 shares in the last quarter. Finally, AE Wealth Management LLC purchased a new position in Johnson & Johnson in the 4th quarter valued at about $1,571,000. Institutional investors own 66.00% of the company’s stock.
Johnson & Johnson (JNJ) traded up 0.71% during mid-day trading on Wednesday, reaching $130.82. 1,637,935 shares of the company were exchanged. The stock’s 50-day moving average is $132.83 and its 200-day moving average is $128.69. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.08. The company has a market cap of $351.12 billion, a P/E ratio of 22.14 and a beta of 0.79.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The company had revenue of $18.84 billion during the quarter, compared to the consensus estimate of $18.94 billion. During the same period last year, the business earned $1.74 EPS. The business’s quarterly revenue was up 1.9% on a year-over-year basis. Equities analysts expect that Johnson & Johnson will post $7.18 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.59%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 56.76%.
In other news, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the sale, the vice president now directly owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the sale, the vice president now directly owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is owned by company insiders.
A number of research analysts have issued reports on the stock. UBS AG restated a “buy” rating and issued a $136.00 target price on shares of Johnson & Johnson in a report on Monday, May 15th. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $132.33 target price on the stock in a report on Thursday, May 18th. J P Morgan Chase & Co upped their target price on shares of Johnson & Johnson from $140.00 to $148.00 and gave the company an “overweight” rating in a report on Wednesday, August 16th. Stifel Nicolaus restated a “hold” rating and issued a $128.00 target price (up from $124.00) on shares of Johnson & Johnson in a report on Thursday, May 18th. Finally, BidaskClub upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have issued a buy rating to the company’s stock. Johnson & Johnson presently has an average rating of “Hold” and a consensus price target of $134.60.
COPYRIGHT VIOLATION NOTICE: “Congress Asset Management Co. MA Sells 910 Shares of Johnson & Johnson (JNJ)” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/06/congress-asset-management-co-ma-sells-910-shares-of-johnson-johnson-jnj.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.